The inflammatory mediator interleukin-1 (IL-1), which is known to be a driver of chronic diseases such as diabetes and hypertension, has recently been identified as a major contributor to ischaemic brain injury. IL-1 is made by the haematopoietic (blood) system and also by cells in the brain. The relative contributions of central versus peripheral sources of IL-1 to brain injury have not been previously investigated. Here, Stuart Allan and colleagues selectively eliminated haematopoietic-derived IL-1 in a chimeric mouse model of ischaemic brain injury. They demonstrate that both sources of IL-1 are important for disease development, but removal of the peripheral source alone is sufficient to improve neurological outcome in the mice. This suggests that therapies that target peripheral IL-1 could be beneficial in brain injury, potentially overriding the need to deliver drugs across the blood-brain barrier. Page 1043
Targeting blood-derived IL-1 to treat brain injury
- Split-screen
- Views Icon Views
- PDF LinkPDF
-
Article Versions Icon
Versions
- Version of Record 01 July 2013
- Share Icon Share
-
Tools Icon
Tools
- Search Site
Targeting blood-derived IL-1 to treat brain injury. Dis Model Mech 1 July 2013; 6 (4): 867. doi:
Download citation file:
Advertisement
Cited by
Virtual Meeting - Developmental Disorders: From Mechanism to Treatment
A collaboration between the Development and Disease Models & Mechanisms journal teams, this virtual Meeting will unite developmental biologists, human geneticists and clinical researchers to focus on building bridges from bench to clinic. Register your interest and find out more.
High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition
Vitamin B1 is shown to prevent nutrition-induced fatty liver in our current Editor’s choice by Hay Davir and his colleagues, when they use sheep as a large-animal model for studying the disease.
Find out more in an interview with the paper's first authors, Mugagga Kalyesubula and Ramgopal Mopuri.
Upcoming grant deadlines
Grants awarded by The Company of Biologists help scientists travel, attend events and host sustainable activities. Make a note of the upcoming application deadlines and find out more about the grants on offer:
DMM Conference Travel Grants
17 May 2021
Sustainable Conferencing Grants
17 May 2021
Travelling Fellowships
31 May 2021
Scientific Meeting Grants
4 June 2021
Call for papers - The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on targeting the RAS pathway.
Other journals from
The Company of Biologists